Csl . Stock Earnings Reports

CSL reported fiscal 2025 results showing continued growth and stronger profitability: Group revenue grew ~5% at constant currency to $15.6bn; NPATA rose 14% and NPAT rose 17%. Free cash flow increased 58%, net debt/EBITDA improved to 1.8x, and the final dividend was increased (total dividend up ~11% to USD 2.92/share). Management announced a major transformation program to simplify the operating model, reprioritize R&D, combine commercial/medical capabilities across businesses, and reduce headcount. Targets include more than USD 0.5bn annual pretax savings by end of FY2028, funded by one-off restructuring charges of ~$700–770m pretax (recognized in FY2026) with a cash impact of $400–450m in FY2026. CSL intends to demerge CSL Seqirus as an independent ASX-listed company in FY2026 (subject to approvals) and reintroduce a multiyear on-market buyback (initially ~AUD 750m in FY2026). Business highlights: CSL Behring grew 6% (PRIVIGEN, HIZENTRA growth; HEMGENIX uptake positive but slower than expected; ANDEMBRY launched late in FY25), CSL Seqirus grew 2% in a weak seasonal market (expanded into Germany/France/Taiwan/Korea; avian flu contracts awarded), and CSL Vifor grew 8% (iron volume growth, strong nephrology launches including TAVNEOS and FILSPARI). FY2026 outlook: Group revenue growth approx. 4–5% CC; NPATA guidance (excluding nonrecurring restructuring) $3.45–3.55bn (7–10% growth CC). Management remains committed to delivering double-digit earnings growth over the medium term but says extraction of the announced savings is required to achieve that target. Key near-term items for investors: execution risk around the transformation (timing of savings largely back-ended to FY27–28), one-off FY26 restructuring charges and cash outflow, demerger execution and timing, new buyback program, and continued monitoring of policy risks (e.g., tariffs, MFN/Medicare reforms) which management says are being monitored but are not assumed to materially affect FY26 guidance.